Semaglutide for the treatment of visceral obesity in people with HIV with body mass index <30 kg/m2 and without diabetes: a randomized clinical trial to explore immune metabolism, systemic and vascular inflammation assessed with Positron Emission Tomography

Condition studied

Adult subjects with HIV infection on stable antiretroviral therapy.

Investigational medicinal product(s)

Every trial of Semaglutide across our registers →

Eligibility

Primary endpoint

Percentage change in visceral adipose tissue (VAT area, cm2) from baseline to Month 12, measured by whole-body DEXA and assessed by readers blinded to treatment allocation.

Endpoint detail

Proportion of participants achieving a reduction of at least 30% in VAT at 12 months. Changes in: body composition, weight and BMI, MASLD, incident diabetes and cardiovascular disease, physical performance and frailty, patient-reported outcomes, immune-metabolic phenotyping, inflammatory biomarkers, and vascular inflammation by [18F] FDG-PET.